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Abstract
Health economists are currently debating, with some suspicion, the relative merits of cost-benefit analysis (CBA), grounded 
in theoretical welfare economics, and the proliferation of social return on investment (SROI), a pragmatic approach of 
developing a triple-bottom line (social, environmental and financial), but not grounded in welfare theory. We argue, in rather 
existential terms, that there is a need to understand the role of heuristics, or prior beliefs, in current ‘best practice’ in CBA 
and SROI. A taxonomy of CBA and SROI is presented, which summarises the origins of the methods, reporting guidance, 
publication checklist of quality of reporting, who is wanting these analytical approaches, and policy decision rule present. 
We argue that a bottom-up SROI is best thought of as localised CBA, building stakeholder involvement right into the fram-
ing of SROI, perhaps addressing or mitigating the effects of prior heuristics in top-down CBA. Behavioural CBA and social 
CBA recognise that people are not rational and that sources of value other than willingness to pay may best reflect social 
values. Standardisation of SROI and comparison with CBA may illuminate the role of prior heuristics and seek to better 
reflect social value in weighing up the costs and benefits of public health interventions at both a local and societal level.
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Key Points for Decision Makers 
SROI is best thought of as localised CBA. A guide is 
proposed for deciding whether SROI or CBA is most 
appropriate in any evaluative situation.
The top-down CBA method applies to the welfare of 
the economy or society as a whole rather than with any 
smaller group within that economy or society (in this 
way, it is different from the bottom-up SROI method, 
which often has a more local commissioning focus).
When designing and implementing public health 
interventions to protect and promote population health, 
we need to remember that people are not rational, and 
instead be aware of heuristics (prior beliefs).
We need to use evaluative methods that recognise the 
role of prior heuristics that better reflect social value in 
weighing up the costs and benefits of public health inter-
ventions at both a local and societal level.
1 Introduction
Cost-benefit analysis (CBA) is an economic method of 
analysis used to assess the costs and benefits of an inter-
vention where both are expressed in monetary units. CBA 
focuses on the overall efficiency or value-for-money of 
one intervention compared to another [1]. Social return on 
investment (SROI) developed from traditional CBA and 
social accounting. SROI is an outcomes-based measure-
ment tool that helps to understand and quantify the social, 
environmental and economic value being created from an 
intervention, and gives a ratio that states how much social 
value (in GBP [£]) is created for every £1 of investment 
[2]. Growing interest in the use of techniques of economic 
evaluation, such as CBA and SROI, in the evaluation of 
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public health interventions to improve population health 
and reduce risk of future ill-health and disability is under-
pinned by the paradigm shift from ‘health services eco-
nomics’ to ‘health economic evaluation’ [3, 4]. Public 
health initiatives to prevent ill-health and reduce health 
inequalities across the population life course often take 
place outside of traditional health care settings, for exam-
ple the National Health Service (NHS) in the United King-
dom (UK). Many public health interventions take place in 
homes, schools, workplaces, and the community, creating 
complexity in economic evaluation [5]. This interest in 
applying economic evaluation methods to public health 
interventions takes us into existentialist considerations, 
not usually the subject of health economics. Existential-
ism is a philosophy rather than a scientific theory. It is a 
philosophy concerned with human beings as being ‘in the 
making’ [6].
This paper explores the philosophical issue of ‘how we 
think about and see the world’, that is, perspective and 
scope of evaluation, how we gather information from 
relevant stakeholders as society as a whole or individual 
stakeholders at a local level, and how we measure costs 
and outcomes in a wide or local public health evaluative 
space using heuristics (which we can think about as ‘rules-
of-thumb’). Heuristics can lead us to attainable answers 
to difficult questions, which may not be the ‘right’ or most 
socially desirable answers, but that use the information 
and evidence we have to hand within a manageable time-
scale. Growing interest in public health economics through 
a paradigm shift from ‘healthcare economics’ to ‘health 
economics,’ allowed for a broader perspective of health 
and causes of inequalities in health to be considered by 
health economists [4].
The National Institute for Health and Care Excellence 
(NICE) [7] recommends the use of CBA and cost conse-
quence analysis (CCA) in the evaluation of public health 
interventions, the latter being a disaggregated method. 
Many public health interventions represent good value for 
money with respect to the NICE threshold of £20,000 to 
£30,000 [8]. However, many commentators feel that the 
quality-adjusted life year (QALY) as an outcome measure 
in cost utility analysis (CUA) is not capable of capturing 
the wide range of relevant outcomes (often across a num-
ber of sectors) with respect to public health interventions 
that aim to improve the health of a population [5].
It is worth pausing to think about the underpinning ideas 
relating to such methodological debate. Daniel Kahne-
man’s [9] book Thinking, Fast and Slow, which explores 
the presence of two systems, System 1 (fast, automatic, fre-
quent, emotional, stereotypic, unconscious) and System 2 
(slow, effortful, infrequent, logical, calculating, conscious), 
has implications for the current debate amongst health 
economists about the similarities and differences between 
‘top-down’ CBA, underpinned by welfare economics, and 
‘bottom-up’ SROI, which is emerging from the field of 
social value calculation [10, 11]. These two methods of anal-
ysis, along with variants such as social CBA and behavioural 
CBA, are gaining more attention with respect to the evalua-
tive space in public health economics [5, 12, 13]. Kahneman 
described a cognitive bias, which he termed ‘what you see 
is all there is’ (WYSIATI), that we use when we try to auto-
matically make sense of partial information in a complex 
world. Kahneman [9] describes how, “Much of the time, the 
coherent story we put together is close enough to reality to 
support reasonable action” (p. 87). Heuristics are a type of 
problem-solving method that allows good-enough solutions 
to be made when decisions need to be made quickly, par-
ticularly when there are complex data. Neth and Gigerenzer 
[14] argued that heuristics are the answer to Simon’s [15] 
question: “How do human beings reason when the condi-
tions for rationality postulated by the model of neoclassical 
economics are not met?” (p. 377).
Health economists have looked on as interest in, and 
the practice of, SROI has increased over the last 10 years 
with some adopting the method [16, 17]. Hutchinson et al 
[11] explored the extent to which academics in the health 
and social care research field, including health economists, 
have adopted SROI methods and assessed the quality of the 
papers they found according to a purpose-made checklist. 
From 868 papers screened, Hutchinson and colleagues iden-
tified only 8 studies that met the criteria for inclusion in their 
systematic review. Of these eight studies, Hutchinson and 
colleagues found study quality to be highly variable. In gen-
eral, relatively high consistency and clarity were observed 
in the reporting of the research question, reasons for using 
this SROI methodology and justifying the need for the study. 
The authors found weaknesses in justifying stakeholders, 
reporting sample sizes, undertaking sensitivity analysis, and 
reporting unexpected or negative outcomes. They argued 
that there was little evidence that academic researchers in 
the health and social care field had advanced SROI methods 
or compared them with CBA methods beyond the Nicholls 
et al. [18] paper. As well as peer-reviewed published papers 
reporting the findings of SROI studies, examples of grey lit-
erature reports of SROI of third sector (i.e., voluntary sector) 
reports can be found on the Social Value UK [19] website.
This paper is, to our knowledge, the first attempt in health 
economics to draw out the similarities and differences in 
CBA and SROI methods and offer a guide to where they 
might be best applied in the evaluation of public health 
interventions. The paper builds on a very useful paper draw-
ing out the similarities and differences in a US non-profit 
social enterprise setting [20]. The remainder of this paper 
is structured as follows. In the following sections we revisit 
the QALY paradigm, extra welfarism and public health; 
review the principles of cost-effectiveness analysis (CEA) 
CBA and SROI, Similarities and Differences
and associated decision rules; explore the similarities and 
differences between CBA and SROI; compare sources of 
monetary values used in CBA and SOI, and finally stop to 
think about the precautionary principle in public health.
2  Revisiting Familiar Territory: 
Cost‑Effectiveness Analysis and Decision 
Rules
NICE [21] recommends the use of CUA in the evaluation 
of most new drugs and technologies. This is derived from 
the evidence-based medicine paradigm in which “well-con-
ducted RCTs can virtually eliminate biases and establish 
the direction of causation of the effect of an intervention” 
(p. 2) [22]. Randomised controlled trials (RCTs) use objec-
tive probabilities akin to base probabilities in the work of 
Kahneman [9] in Thinking, Fast and Slow. These are dis-
tinct from subjective probabilities, which can lead to bias 
in forming conclusions, which are arguably present in the 
use of heuristics or rules of thumb. In its Guide to the meth-
ods of technology appraisal, NICE [23] recommends that 
an intervention’s effectiveness should be established from 
external evidence with sufficient certainty. In their 2018 
manual for guidelines in public health, NICE [21] broad-
ens the evidence-based medicine criteria to allow subjec-
tive measures of effect, following the Bradford Hill criteria 
for judging causality. In public health, this broadening is 
necessary where trials are often underpowered or necessary 
evidence does not exist, otherwise trials would have to be 
extremely large and prohibitively expensive, leading to the 
use of evidence from natural experiments, non-controlled 
studies, and expert opinion [21].
In the extra-welfarist QALY paradigm, the additional cost 
of an intervention compared with usual care is divided by 
the quality-adjusted survival effects of the intervention (over 
and above those of usual care) to produce an incremental 
cost per QALY (also known as an incremental cost-effec-
tiveness ratio [ICER]) [22]. The underlying assumption is a 
societal goal of QALY maximisation. Fischer and Ghelardi 
[22] have argued that decision makers using CEA are risk 
neutral, rather like large insurers pooling risk. This means 
they use a decision rule of whether an ICER for a particu-
lar intervention falls above or below the NICE threshold 
regardless of sampling variability. Fischer and Ghelardi 
questioned whether national health systems such as the NHS 
in the UK are in fact risk neutral or could be risk averse 
and pay more in the case of potential public health crises. 
This has undoubtedly been borne out during the COVID-19 
pandemic. For example, in response to the expected surge 
of patients diagnosed with COVID-19, the NHS undertook 
several measures to ensure sufficient bed capacity, includ-
ing block-buying capacity in independent hospitals, and 
the Chancellor of the Exchequer stated in Parliament that, 
“Whatever extra resources our NHS needs to cope with coro-
navirus—it will get” [24]. The decision-theory rules of CEA 
break down in such circumstances, as they assume risk neu-
trality and the presence of a budget envelope [25].
Back in 1992, Birch and Gafni [25] explored the theo-
retical underpinnings of CEA and CUA, and whether they 
do indeed meet societal goals. Birch and Gafni [25] argued 
that CEA, operationalised through CUA, is inconsistent with 
welfare economics objectives. They put forward alternative 
strategies for achieving such welfare economics objectives. 
Using quotes from Alice in Wonderland by Lewis Carroll, 
their paper asked whether this information used in eco-
nomic evaluation, in line with current guidance, leads us 
to our chosen objectives (or where we want to be). They 
argued the need to examine whether CEA and CUA opera-
tionalise meeting defined societal goals. They argued that 
if “the objective is to evaluate programmes from a welfare 
economics perspective, then the use of cost-effectiveness 
or cost-utility methods should be applied in the context of 
integer programming problems [a heuristic programming 
technique]. Alternatively, welfare economic goals could be 
pursued by adopting a higher level of economic evaluation, 
i.e., cost-benefit analysis” (p. 295) [25]. CBA, unlike CEA 
and CUA, has its foundations in welfare economics.
Birch and Gafni [25] essentially were exploring the fact 
that CEA does not take account of societal or organisational 
budget constraint in itself. They argued that simple applica-
tion of this cost-effectiveness ratio to decide between inter-
ventions “need not lead to the maximization of benefits from 
a fixed resource pool, nor to minimizing the cost of achiev-
ing a given objective” (p. 284) [25]. Essentially, without 
a budget constraint we ignore the principle of opportunity 
cost. This is an idea that was championed by Karl Claxton 
prior to the COVID-19 pandemic. He argued that the NICE 
threshold range of £20,000 to £30,000 per QALY, which 
has been implemented since 2004, is not based on evidence, 
and instead, a threshold of £13,000 per QALY should be 
used as it better reflects the opportunity cost of producing 
an additional QALY in the NHS [26]. Today, we are familiar 
with the concept that extra-welfarist, rather than welfarist, 
principles underpin such decision rules by NICE, that is, that 
of QALY maximisation [27].
Birch and Gafni [25] argued that, in theory, CUA was 
consistent with welfare economics theory of production and 
product mix using a QALY production frontier model, but 
that the decision rules of CUA recommended in the methods 
literature did not address the issue of allocative efficiency 
(i.e., how we achieve specified societal goals). They argued 
that for all this to work out, we need to assume that 1) the 
objective is to maximise QALYs produced from a given 
resource pool, and 2) the value of a given change in health 
status is assumed to be of equal value to society, irrespective 
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of who receives it [25]. This extra-welfarist paradigm is dif-
ferent from the welfarist paradigm which acknowledges 
heterogeneity in willingness to pay (WTP) (compensating 
variation for a unit of health gain). We return to this WTP 
issue later in the paper.
3  Exploring the Similarities and Differences 
Between Cost‑Benefit Analysis (CBA) 
and Social Return on Investment (SROI)
Below are brief descriptions of a number of methods of eco-
nomic evaluation which are increasingly being advocated 
and applied in the evaluation of public health interventions. 
As stated above, with respect to the evaluation of public 
health interventions, with potential costs and benefits span-
ning a range of sectors beyond the health sector, and with 
multiple policy goals, over the last decade NICE has rec-
ommended the use of CBA and disaggregated CCA, and 
developed a range of ROI tools and explored the use of SROI 
[7, 13]. The following subsections complement our taxon-
omy of CBA and SOI shown in Table 1, which summarises 
the origins of the methods, reporting guidance, publication 
checklists of quality reporting, who is wanting these analyti-
cal approaches, and policy decision rules present.
3.1  Return on Investment (ROI)
ROI is a performance measure used to evaluate the effi-
ciency of an investment or compare the efficiency of a 
number of different investments. It tries to directly meas-
ure the amount of financial return on a particular invest-
ment relative to the investment’s cost. To calculate ROI, 
the net benefit (or return) of an investment is divided by 
the cost of that investment. The result is expressed as a 
percentage or ratio. ROI analysis has been advocated and 
is being used in public health to quantify the impact of 
recent disinvestment in public health, during a decade of 
austerity and coinciding with a move out of the NHS and 
into local authority in England, UK [39]. A recent review 
with 52 included studies found a median ROI of 14.3–1, 
and a median cost-benefit ratio (CBR) of 8.3. The median 
ROI for all 29 local public health interventions was 4.1–1, 
and a median CBR of 10.3. Even larger benefits were 
reported in 28 studies analysing nationwide public health 
interventions; the median ROI was 27.2, and median CBR 
was 17.5 [39]. The authors interpreted these results as 
demonstrating public health interventions as highly cost 
saving and that such cuts in spending on public health ser-
vices represented a false economy. There were a handful 
of studies with a negative ROI or CBR in this review, for 
example Nichol [40]. To address the limitation of defining 
what constitutes a ‘public health intervention’, Masters 
et al used Acheson’s [41] broad definition of public health 
when considering their search strategy. By including the 
various fields of public health, the authors establish that 
these 52 included studies are representative of public 
health interventions in general.
Public Health England [28] have published resources 
to help local commissioners achieve value for money by 
estimating the ROI and cost effectiveness (cost per QALY) 
of public health programmes, including how to:
• Assess which interventions provide the best value for 
money, by calculating their costs, benefits and ROI
• Make the most of a budget by deciding how to split 
resources across different public health programmes
• Compare costs, savings and clinical outcomes
Public Health England [28] have produced interactive 
tools for the following health conditions and services: 
older adults; colorectal cancer; NHS Diabetes Prevention 
Programme; end-of-life care; weight management; oral 
health in pre-school children; mental health service; mus-
culoskeletal conditions; movement into employment; falls 
prevention; Best Start in Life; air pollution; contraceptive 
services, and cardiovascular disease. For example, the 
development of the older adults’ NHS and social care ROI 
tool presents ROI for four different analytical perspectives: 
NHS financial ROI (where benefits are measured exclu-
sively as gross NHS savings for every £1 spent by com-
missioners on the intervention); social care financial ROI 
(where benefits are measured exclusively as gross social 
care savings for every £1 spent by commissioners on the 
intervention); financial ROI (where benefits are measured 
as gross NHS and social care savings for every £1 spent by 
commissioners on the intervention), and SROI (where ben-
efits include gross NHS and social care savings in addition 
to monetised QALYs for every £1 spent by commissioners 
on the intervention) [42].
3.2  Social Return on Investment (SROI)
SROI was originally developed by the Roberts Enterprise 
Fund (REDF) in 1996 [43]. Since then, there has been a 
gradual revision of the original methodology, which has led 
to the ‘triple bottom line’ approach, underpinned by blended 
value accounting theory [44–47]. SROI is an evaluative 
framework that helps organisations to quantify the social, 
environmental and economic value being created by pro-
ducing a ratio that states how much social value (in mon-
etary terms) is created for every £1 of investment [2]. In the 
UK, SROI has been championed by the New Economics 
Foundation (NEF). NEF offers consultancy and training on 
the methodology and practice needed to conduct an SROI 
analysis to clients such as local authorities, universities, 
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public health services, charities, and community groups. 
A key principle of SROI is understanding how and what 
changes occur as a result of an intervention (e.g., social, 
environmental or economic). This guides the approach to 
selecting which outcomes to measure and value (in order to 
provide evidence that change has taken place). Social pre-
scribing, also known as community referral, is a way for 
health professionals to refer people to local, non-clinical 
services (such as nature-based activities) to support health 
and well-being [48]. SROI is increasingly being used as a 
method for analysing social prescribing interventions as it 
takes into account ‘well-being’ impacts into the analysis 
[49]. Social prescribing is an example of how SROI can be 
applied to measure localised CBA.
3.3  Cost‑Benefit Analysis (CBA)
CBA was formalised in the US Flood Control Act of 1936 
[50], which asserted that the federal government had a 
responsibility to support flood control activities “if the ben-
efits to whomsoever they may accrue are in excess of the 
estimated costs, and if the lives and social security of people 
are otherwise adversely affected” (p. 71). The Kaldor-Hicks 
criteria of hypothetical compensation argued that a public 
policy was justified if it produced social gains in excess of 
social losses so that it was possible for winners from the 
policy to compensate losers even if compensation did not 
actually take place—the foundation of new applied welfare 
economics from the 1950s onwards. Hicks [51] argued that 
the business of the economist is “to estimate as far as he 
[or she] can the gains and losses that are likely to accrue, 
to various classes, or sections of the population, from the 
proposed action” (p. 366) with a view to hypothetical com-
pensation being possible. Adler and Posner [52] rejected the 
Kaldor-Hicks approach, emphasised the social objective of 
improving overall well-being with considerable emphasis 
on distributional issues, for example, by statistical averag-
ing of group gains and losses over time and space. There is 
growing interest particularly in environmental economics 
in the inclusion of equity weights in CBA and that it may 
make a considerable difference to policy recommendations. 
However, economists applying mainstream CBA have been 
reluctant to use such weights because of the uncertainty 
about their values and the wide range they could take [53].
3.4  Social Cost‑Benefit Analysis (CBA)
Little and Mirrlees [34] and the United Nations Industrial 
Development Organisation (UNIDO) developed social CBA 
techniques in the late 1960s. Social CBA is a marginal analy-
sis technique that assesses the impact of different options on 
social welfare [35], taking into account the social, economic, 
environmental and financial impacts. This technique can be 
used to express the social costs and social benefits of gov-
ernment policies to society in monetary terms so that the 
consequences of a range of policies can be compared using a 
common metric. Change in welfare is measured as the aggre-
gate WTP for the effects of a certain policy intervention. 
Social CBA has been championed in the Netherlands with 
respect to the evaluation of transport and road system plan-
ning including congestion charges, and tobacco and alcohol 
pricing and policy [54–56].
3.5  Behavioural Cost‑Benefit Analysis (CBA)
CBA is based on the neoclassical welfare economics para-
digm, which assumes that people maximise their long-term 
best interest, have stable preferences, and are consistent 
rational actors. Behavioural CBA involves bringing insights 
from behavioural economics into CBA to reflect the fact 
that people actually do not always behave rationally [57]. 
Behavioural economics can provide an empirically informed 
perspective on CBA, including the important realisation 
that even subtle features of the environment or the design 
of public health interventions can have meaningful impacts 
on behaviour [58]. As such, behavioural economics under-
pins the ‘nudge theory’, which argues the case for positive 
reinforcement and indirect suggestions as ways to influence 
the behaviour and decision making of groups or individuals 
[59].
With respect to the economic evaluation of public health 
interventions, it has proved challenging sometimes to 
capture economic benefits, for example, CBA of the Sure 
Start Programme in the UK for young families [60]. Public 
health interventions can fail to be effective due to assump-
tions about rationality, which may be limited or bounded as 
a result of limited willpower, addiction, social norms, and 
the context in which choices are made [58]. The behavioural 
economics approach, applied to CBA, draws on related fields 
of psychology and neuroscience.
Behavioural economics has implications for the way we 
conduct CBA as a result of this, particularly whether we 
should actually use WTP estimates as a basis for shadow 
prices where no market values exist, for example, in the case 
of a public good such as prevention. Asking people to state 
their preference for what they would pay for a hypothetical 
public health intervention to which they may not respond 
rationally may lead to misleading non-market values which 
could influence CBA calculations. This applies equally to 
the argument that a distinction should be made between 
decision-utility and experienced-utility, making the norma-
tive assumption that the allocation of resources should be 
based on experienced-utility rather than decision-utility. 
This approach favours prospect theory as a basis for CBA 
CBA and SROI, Similarities and Differences
because decision making under uncertainty departs from 
expected utility theory [61, 62]. Prospect theory, developed 
by Daniel Kahneman and Amos Tversky in 1979, under-
pins behavioural economics and aims to describe the actual 
behaviour of people and challenges the expected utility 
theory developed by John von Neumann and Oskar Mor-
genstern. Prospect theory involves individuals weighing up 
their potential losses and gains of an action and does not 
require the assumptions of expected utility theory, that is, 
rationality [61, 62]. This has implications for what discount 
rates are chosen in CBA because of present-bias, due to irra-
tional impatience. Overall, behavioural economics cautions 
health economists to the framing of WTP questions and how 
these might influence the outcome of applying CBA in the 
evaluation of public health interventions where health and 
other benefits are often accrued far into the future. Field 
experiments are becoming more common beyond laboratory 
experiments to test out whether irrational behaviour as found 
in the laboratory would influence the calculation of shadow 
prices representing people’s behaviour in real life. This is 
an effort to use evidence to improve the conduct of CBA 
[57]. The UK government have recognised the importance 
of behavioural economics in establishing the Behavioural 
Insights Team (https:// www. bi. team/).
3.6  Comparison of Calculation Methods
In Box 1 below we set out the formulae for the calculation 
of ROI, SROI and benefit cost ratios.
Box 1 Calculating return on investment (ROI), social ROI 
(SROI) and cost-benefit analysis (CBA)
In theory, the methods discussed above in Box 1 all share 
the stages of identifying, measuring and valuing the costs 
and benefits, but they may vary in perspective, range and 
the extent to which they require all items to be monetised.
4  Sources of Value for Cost‑Benefit Analysis 
(CBA) and Social Return on Investment 
(SROI)
In CBA, where there is no market price, analysts have used 
stated preference WTP, also known as contingent valu-
ation (CV), as a means of gaining a shadow price [32]. 
Compared with the number of cost-effectiveness and cost-
utility studies undertaken as health technology assessment 
(HTA), there have been relatively few cost-benefit studies 
in health and social care and we find ourselves back in the 
1990s when the idea of the use of CBA in health economics 
was first explored [63]. CBA has been used more widely 
in environmental economics and more recently SROI has 
been adopted by the third sector across the economy in the 
evaluation of social programmes [64–66]. In 1991, Gafni 
argued that WTP could be used both in a private individual 
and public policy setting to establish non-market values. His 
starting point was that the general question that CBA sets 
out to answer is whether one or a number of programmes 
should be undertaken at all and, if investable funds are lim-
ited, which programmes among those predicted to gener-
ate a surplus of benefit over costs should be selected [67]. 
This top-down CBA method applies to the welfare of the 
economy or society as a whole rather than with any smaller 
group within that economy or society (in this way, it is dif-
ferent from the bottom-up SROI method, which often has a 
more local commissioning focus). In line with the Potential 
Pareto Improvement Criterion, welfare is measured by an 
individual’s maximum WTP for the good or service gained 
as the measure of benefits or the minimum level of compen-
sation for them to give up that good or service. This is based 
on the assumption of ‘rationality’, which links back to the 
more recent enquiry of behavioural economists as to whether 
such rationality exists. The WTP and contingent valuation 
literature has developed into the discrete choice experiment 
methodology over the last two decades, involving assump-
tions of rationality [68–70].
SROI is described as a form of CBA and can be thought 
of as a localised CBA, which aims to calculate the triple bot-
tom line for a given geographical area population or defined 
group of stakeholders rather than the whole of the economy 
or society as in CBA. SROI often uses values from the grow-
ing source of social value estimates used in social well-being 
valuation, such as the Social Value Bank [10, 71]. These 
could arguably be used more widely for CBA but have not 
been to date perhaps on theoretical grounds.
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5  The Precautionary Principle in Public 
Health
The precautionary principle emerged during the 1970s in 
German environmental law, where it was referred to as Vor-
sorgeprinzip. The precautionary principle enables decision 
makers to adopt precautionary measures when scientific 
information is uncertain and there is potential for causing 
harm. While science can improve our knowledge base, it can 
rarely provide certainty, and so decisions must be made on 
the basis of the best available information, while erring on 
the side of caution. We have seen the use of the precaution-
ary principle internationally in the handling of the COVID-
19 pandemic [72, 73]. The precautionary principle in rela-
tion to the evaluation of public health interventions, as put 
forward by Fischer and Ghelardi [22], reverses the onus of 
proof of effectiveness and cost effectiveness of interventions 
designed to reduce harm and it seems particularly relevant 
at a time of the COVID-19 pandemic. The UK government 
acted without full evidence but aware that the direct health 
effects of COVID-19 on society would be amplified by the 
wider economic impacts on health resulting from economic 
hardship through (1) public and private indebtedness; (2) an 
uneven impact of lockdown across regions and countries, 
and (3) poverty and subsequent effects on health and access 
to health and social care [74]. Fisher and Ghelardi [22] state 
that, “The expectation in Public Health is that interventions 
employed to reduce harm will not actually increase harm, 
where ‘harm’ in this context does not include opportunity 
cost” (p. 1). This is contrary to the evidence-based medicine 
paradigm where the onus is to demonstrate clinical effective-
ness and cost effectiveness with sufficient certainty before 
the introduction of a new drug or device. These authors con-
sider the cost of society taking precautions to protect public 
health or mitigate the effects of poverty, for example, and 
that these precautions are not costless. The Rio Declaration 
on Environment and Development [75] states that, “In order 
to protect the environment, the precautionary approach shall 
be widely applied by States according to their capabilities. 
Where there are threats of serious or irreversible damage, 
lack of full scientific certainty shall not be used as a reason 
for postponing cost-effective measures to prevent environ-
mental degradation” (principle 15).
The problem in applying the precautionary principle 
across different sectors is that there is no agreed definition 
about the degree of precaution and appropriate costs, who 
bears those costs and who may reap the subsequent benefits. 
It can be argued, as we attempt here, that CBA and SROI 
are actually more closely aligned to the decision theory 
Bayesian approach to the evaluation of public health inter-
ventions put forward by Fischer et al [12] than CEA based 
on RCT evidence. We argue that the use of a posterior com-
bination of existing and new updated evidence from a range 
of sources as well as, or in the absence of, RCT evidence, 
and awareness of potential ‘bias’, along the lines of Kahne-
man’s [9] ‘what you see is all there is’ (WYSIATI) principle 
describes how analysts might take a viewpoint of society or 
a local community in the case of CBA and SROI. To this 
end, new information has value in that it can alter or improve 
decision making. Fischer et al argue that decision theory 
aims to forecast the likely impact of a public health interven-
tion and that then it is up to policymakers to weigh up wider 
costs and outcomes beyond the direct health impacts desired. 
The processes of CBA and SROI really aim to capture these 
and place monetary values on them where possible.
Aware of the danger of bias, in a US non-profit setting of 
the evaluation of social enterprises, Cordes [20] alludes to 
the danger of thinking ‘fast’ using readily available values 
in a heuristic sense “because of difficulties in monetization, 
attempting to quantify non-profit performance with either 
SROI analysis or CBA will tend to favor activities with out-
comes that are readily translated into dollars, and/or create 
incentives for non-profits to focus more on those activities 
that can be monetized” (p. 104).
6  Choice of Cost‑Benefit Analysis (CBA) 
or Social Return on Investment (SROI) 
Methods
In more stable times, budget constraints require weighing up 
the costs and benefits of using scarce resources in different 
ways at both the societal and local level. Below is a guide 
for health economists to think about, which methods might 
be most appropriate to provide evidence for policy makers 
at a societal or local level (Fig. 1).
Recent research in the field of public health economics 
has identified that many health and local authority com-
missioners and their public health colleagues want to know 
is really a version of localised CBA, across sectors, which 
is why they have been drawn to SROI [76]. Where there is 
an appetite for shared budgets and joined up working at a 
local level, SROI and ROI evidence can make a meaningful 
contribution to the evidence base on which public health 
service commissioning decisions are made. However, it 
would be naïve not to acknowledge the influence of local 
politics and political horizons on decision making. Local 
stakeholders may still feel very restricted by the structure 
of individual departmental budgets and the political conse-
quences of not prioritising the goals set within those indi-
vidual silos.
CBA and SROI, Similarities and Differences
6.1  Should We Use Multiple Methods of Analysis?
Ultimately, health economists are, or should be, concerned 
with the measurement of opportunity cost. This sometimes 
gets lost. Methods such as ROI and SROI are criticised 
because they do not measure or account for opportunity 
cost. CEA and CUA lend themselves to decision rules such 
as reference to payer thresholds. CBA, SROI and ROI facili-
tate rankings of benefit cost ratios. CCA is disaggregated 
leaving the decision maker to weigh up the relative merits 
of alternatives without a common denominator. It has been 
suggested that we should apply multiple methods of analy-
sis, which at one level enables the capture of a wide range 
of costs and benefits, but we are left with the decision rule 
challenge. If one method of analysis provides evidence that 
leads to a conclusion that an intervention should be funded 
and another method contradicts that conclusion, relative to 
some decision rule, the decision maker or commissioner of 
services is none the wiser. If we choose to only use one 
method of analysis, then we need to be very clear and open 
about the heuristics or prior beliefs that underpin and bound 
the perspective and range of costs and benefits captured by 
that method.
7  Discussion
When addressing the question of whether a monetary value 
could be put on a human life in the early days of the develop-
ment of CBA or CUA, Mishan described Broome’s scepti-
cism as “faint-hearted intellectual doodling” [77–79]. We 
hope we have done a little better than that in this paper in 
exploring the similarities and differences between CBA and 
SROI methodologies and their use in public health econom-
ics today. CBA and SROI are heavily dependent on the heu-
ristics and value judgements that underpin their perspective, 
range of costs and outcomes captured and valued, and time 
horizon chosen. As analysts, our choice of perspective, and 
hence the range of evidence included in our calculations, 
and indeed the sources of that evidence, determine the bias 
that shape our reality. We started with the quote from Daniel 
Kahneman [9], ‘what you see is all there is’ (WYSIATI), 
because it sums up the fact that we each, as researchers, 
define and interpret our own reality, and that this can greatly 
influence the answers we come to in our health economics 
analysis, and the subsequent use of such evidence by, for 
example, NICE or local commissioners. This subsequently 
shapes the services that end up being commissioned and 
thereby influences the health of the population at a local or 
national level.
Fig. 1  The importance of heu-
ristics in cost-benefit analysis 
(CBA) and social return on 
investment (SROI): a decision 
guide in public health
Is the issue being considered of specific 
local importance or relevance?
For example, this could be a public 
health intervention being evaluated that 
has the potential to affect all of society 
at a national level (e.g. screening in a 
pandemic, alcohol pricing, salt content 
in food, food labelling, clean air 
legislation).
For example, there could be a number 
of different local stakeholders upon 
whom costs and benefits may fall.
For example, local information may be 
more relevant than national information 
(e.g. consideration of joint 
commissioning between agencies - 
local authority, NHS, police, schools, 
transport, environmental agencies).
SROI will be an appropriate method of 
analysis.




Is the public health issue under 
consideration one that applies across 
the whole population?
YES
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Behavioural economists are showing us now that peo-
ple are far from rational. This is important in the design 
and implementation of public health interventions to pro-
tect and promote population health. As health economists, 
we do need to revisit the assumptions of welfare economics 
before just accepting the results of CBA and SROI analy-
ses. The SROI methodology has chosen to routinely source 
shadow prices and social values from HACT and the Social 
Value Bank, for example, in place of WTP used in CBA. 
These values are drawn from four large national UK datasets 
that include data on well-being and life circumstances: Brit-
ish Household Panel Survey [80]; Understanding Society 
[81]; the Crime Survey for England and Wales [82], and 
the Taking Part Survey [83]. These sources are aimed to 
be representative of the population as a whole; however, 
we have to acknowledge that there will be groups within 
the population with very different views. Social preferences 
are multimodal and there may well be distinct groups. An 
example of this would be current attitudes to receiving the 
vaccination against COVID-19.
8  Conclusion
The news is good, aligned with decision theory and the pre-
cautionary principle, the current debate over scrutinising 
and standardising SROI and comparing it to CBA may end 
up improving the usefulness of CBA and SROI as evaluative 
methods that recognise the role of prior heuristics. In the 
UK, measuring social value has become embedded in UK 
legislation, for example, the Public Services (Social Value) 
Act 2012 [84] requires public sector commissioners to factor 
in economic, social and environmental well-being in connec-
tion with public services contracts. Health economists using 
CBA and SROI methods are seeking to better reflect social 
value in weighing up the costs and benefits of public health 
interventions at both a local and societal level.
Acknowledgements This paper came about from engaging discus-
sions that ran across two sessions at the January 2020 Health Econo-
mists’ Study Group (HESG) meeting in Newcastle, UK. With thanks 
to Professor Aki Tsuchiya, University of Sheffield, for reading and 
commenting on the initial draft of this manuscript. We also thank Dr. 
Carys Jones and Dr. Ned Hartfiel, Bangor University, for reading and 
commenting on a later version of this manuscript.
Declarations 
Funding Health and Care Economics Cymru provided funding for 
the development of this paper. Health and Care Economics Cymru 
is funded by Welsh Government through Health and Care Research 
Wales.
Conflict of interest Not applicable.
Availability of data and material Not applicable.
Ethics approval Not applicable.
Consent to participate Not applicable.
Consent for publication Not applicable.
Code availability Not applicable.
Author contributions RTE came up with the review concept and 
drafted the manuscript. CLL drafted the manuscript. Both authors read 
and approved the final manuscript.
Open Access This article is licensed under a Creative Commons Attri-
bution-NonCommercial 4.0 International License, which permits any 
non-commercial use, sharing, adaptation, distribution and reproduction 
in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Com-
mons licence, and indicate if changes were made. The images or other 
third party material in this article are included in the article’s Creative 
Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons 
licence and your intended use is not permitted by statutory regula-
tion or exceeds the permitted use, you will need to obtain permission 
directly from the copyright holder. To view a copy of this licence, visit 
http:// creat iveco mmons. org/ licen ses/ by- nc/4. 0/.
References
 1. Mishan EJ. Cost-benefit analysis. London: Allen and Unwin; 
1971.
 2. New Economics Foundation Consulting. Social return on invest-
ment. 2020. https:// www. nefco nsult ing. com/ our- servi ces/ evalu 
ation- impact- asses sment/ prove- and- impro ve- toolk its/ sroi/ 
Accessed 15 June 2020.
 3. Buck D. Local action on health inequalities: understanding the 
economics of investments in the social determinants of health. 
London: Public Health England; 2014.
 4. Edwards RT. Paradigms and research programmes: is it time to 
move from health care economics to health economics? Health 
Econ. 2001;10(7):635–49.
 5. Edwards RT, McIntosh E, editors. Applied health economics for 
public health practice and research. Oxford: Oxford University 
Press; 2019.
 6. Sartre J-P. Existentialism is a humanism. London: Yale University 
Press; 2007.
 7. National Institute for Health and Care Excellence. Methods for 
the development of NICE public health guidance (third edition). 
2012. https:// www. nice. org. uk/ proce ss/ pmg4/ resou rces/ metho ds- 
for- the- devel opment- of- nice- public- health- guida nce- third- editi 
on- pdf- 20079 67445 701 Accessed 15 June 2020.
 8. Owen L, Fischer A. The cost-effectiveness of public health inter-
ventions examined by the National Institute for Health and Care 
Excellence from 2005 to 2018. Public Health. 2019;169:151–62.
 9. Kahneman D. Thinking, fast and slow. London: Penguin; 2011.
 10. Housing Association’s Charitable Trust. Social value bank cal-
culator 4.0. 2018. https:// www. hact. org. uk/ value- calcu lator. 
Accessed 15 June 2020.
 11. Hutchinson CL, Berndt A, Forsythe D, Gilbert-Hunt S, George S, 
Ratcliffe J. Valuing the impact of health and social care programs 
using social return on investment analysis: how have academics 
CBA and SROI, Similarities and Differences
advanced the methodology? A systematic review. BMJ Open. 
2019;9(8):e029789.
 12. Fischer AJ, Threlfall A, Meah S, Cookson R, Rutter H, Kelly MP. 
The appraisal of public health interventions: an overview. J Public 
Health. 2013;35(4):488–94.
 13. National Institute for Health and Care Excellence. Supporting 
investment in public health: review of methods for assessing cost 
effectiveness, cost impact and return on investment. 2011. https:// 
www. nice. org. uk/ media/ defau lt/ About/ what- we- do/ NICE- guida 
nce/ NICE- guide lines/ Public- health- guide lines/ Addit ional- publi 
catio ns/ Cost- impact- proof- of- conce pt. pdf. Accessed 15 June 
2020.
 14. Neth H, Gigerenzer G. Heuristics: Tools for an uncertain world. 
In: Scott R, Kosslyn S, editors. Emerging trends in the social and 
behavioral sciences: an interdisciplinary, searchable, and linkable 
resource. New York: Wiley; 2015. p. 1–18.
 15. Simon HA. The scientist as problem solver. In: Klahr K, Kotovsky 
S, editors. Complex information processing: the impact of Herbert 
A. Simon. Hillsdale: Lawrence Erlbaum; 1989. pp. 377–98.
 16. Jones C, Windle G, Edwards RT. Dementia and imagination: a 
social return on investment analysis framework for art activities for 
people living with dementia. Gerontologist. 2020;60(1):112–23.
 17. Ashton K, Schröder-Bäck P, Clemens T, Dyakova M, Stielke A, 
Bellis MA. The social value of investing in public health across 
the life course: a systematic scoping review. BMC Public Health. 
2020;20:1–8.
 18. Nicholls J, Lawlor E, Neitzert E, Goodspeed T. A guide to social 
return on investment. Office of the third sector, Cabinet Office. 
2009. http:// www. bond. org. uk/ data/ files/ Cabin et_ office_ A_ guide_ 
to_ Social_ Return_ on_ Inves tment. pdf. Accessed 15 June 2020.
 19. Social Value UK. Report database. 2020 http:// www. socia lvalu 
euk. org/ report- datab ase. Accessed 15 June 2020.
 20. Cordes JJ. Using cost-benefit analysis and social return on invest-
ment to evaluate the impact of social enterprise: promises, imple-
mentation, and limitations. Eval Program Plann. 2017;64:98–104.
 21. National Institute for Health and Care Excellence. Developing 
NICE guidelines: the manual. 2018. https:// www. nice. org. uk/ 
proce ss/ pmg20/ chapt er/ intro ducti on- and- overv iew Accessed 17 
June 2020.
 22. Fischer AJ, Ghelardi G. The precautionary principle, evidence-
based medicine, and decision theory in public health evaluation. 
Front Public Health. 2016;7(4):107.
 23. National Institute for Health and Care Excellence. Guide to the 
methods of technology appraisal. 2013. https:// www. nice. org. uk/ 
proce ss/ pmg9/ resou rces/ guide- to- the- metho ds- of- techn ology- 
appra isal- 2013- pdf- 20079 75843 781. Accessed 17 June 2020.
 24. National Health Service England. Next steps on NHS response to 
COVID-19: letter from Sir Simon Stevens and Amanda Pritchard, 
17 Mar 2020. https:// www. engla nd. nhs. uk/ coron avirus/ wp- conte 
nt/ uploa ds/ sites/ 52/ 2020/ 03/ 20200 317- NHS- COVID- letter- 
FINAL. pdf. Accessed 17 June 2020.
 25. Birch S, Gafni A. Cost effectiveness/utility analyses: do current 
decision rules lead us to where we want to be? J Health Econom-
ics. 1992;11:279–96.
 26. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, 
Devlin N, Smith PC, Sculpher M. Methods for the estimation of 
the National Institute for Health and Care Excellence cost-effec-
tiveness threshold. Health Technol Assess. 2015;19(14):1–542.
 27. Cookson R, Claxton K, editors. The humble economist: Tony 
Culyer on health, health care and social decision making. York: 
University of York Centre for Health Economics; 2012.
 28. Public Health England. Health economics: a guide for public 
health teams. 2020a. https:// www. gov. uk/ guida nce/ health- econo 
mics-a- guide- for- public- health- teams# the- cost- effec tiven ess- of- 
speci fic- topic- areas Accessed 17 June 2020.
 29. Fujiwara D. Measuring the social impact of community invest-
ment: the methodology paper. London, England: Housing Asso-
ciations Charitable Trust (HACT). 2014 https:// hact. org. uk/ sites/ 
defau lt/ files/ uploa ds/ Archi ves/ 2014/3/ HACT% 20Met hodol ogy% 
20Pap er% 20FIN AL. pdf. Accessed 17 June 2020.
 30. Fujiwara D. The seven principle problems of SROI. London, 
England: Simetrica Ltd. 2015. http:// www. socia lvalu euk. org/ 
app/ uploa ds/ 2016/ 03/ The% 20Sev en% 20Pri nciple% 20Pro blems% 
20with% 20SROI_ Daniel% 20Fuj iwara. pdf. Accessed 17 June 
2020.
 31. Banke-Thomas AO, Madaj B, Charles A, van den Broek N. Social 
return on investment (SROI) methodology to account for value for 
money of public health interventions: a systematic review. BMC 
Public Health. 2015;15:582–95.
 32. McIntosh E, Clarke P, Frew E, Louviere JJ. Applied methods of 
cost-benefit analysis in health care, vol. 4. Oxford: Oxford Uni-
versity Press; 2010.
 33. Sanghera S, Frew E, Roberts T. Adapting the CHEERS state-
ment for reporting cost-benefit analysis. Pharmacoeconomics. 
2015;33:533–4.
 34. Little I, Mirrlees J. Project appraisal and planning for developing 
countries. London: Heinemann Educational; 1974.
 35. HM Treasury. The Green Book: Central government guidance on 
appraisal and evaluation. 2018. https:// assets. publi shing. servi ce. 
gov. uk/ gover nment/ uploa ds/ system/ uploa ds/ attac hment_ data/ file/ 
685903/ The_ Green_ Book. pdf. Accessed 10 May 2020.
 36. Edwards W. The theory of decision making. Psychol Bull. 
1954;51:380–417.
 37. Simon HA. A behavioral model of rational choice. Santa Monica: 
The RAND Corporation; 1953.
 38. Hölzinger O, Grayson N. Birmingham health economic assess-
ment and natural capital accounts: revealing the true value of 
council-managed parks and greenspaces. Birmingham, England: 
Birmingham City Council; 2019.
 39. Masters R, Anwar E, Collins B, Cookson R, Capewell S. Return 
on investment of public health interventions: a systematic review. 
J Epidemiol Community Health. 2017;71(8):827–34.
 40. Nichol KL. Cost-benefit analysis of a strategy to vaccinate 
healthy working adults against influenza. Arch Intern Med. 
2001;161(5):749–95.
 41. Acheson D. Public health in England: the report of the committee 
of inquiry into the future development of the public health func-
tion. London: Stationery Office Books; 1988.
 42. Public Health England. The older adults’ NHS and social care 
return on investment tool. 2020b. https:// assets. publi shing. servi 
ce. gov. uk/ gover nment/ uploa ds/ system/ uploa ds/ attac hment_ data/ 
file/ 860613/ Older_ adults_ NHS_ and_ social_ care_ return_ on_ inves 
tment_ tool_-_ Final_ report. pdf. Accessed 10 May 2020.
 43. REDF. SROI methodology: analyzing the value of social purpose 
enterprise within a social return on investment framework. San 
Francisco, CA: REDF; 2000.
 44. Krlev G, Münscher R, Mülbert K. Social Return on Investment 
(SROI): state-of-the-art and perspectives-a meta-analysis of prac-
tice in Social Return on Investment (SROI) studies published 
2002–2012. 2013. https:// www. soz. uni- heide lberg. de/ centre- for- 
social- inves tment/ Accessed 10 May 2020.
 45. Tuan MT. Measuring and/or estimating social value creation: 
Insights into eight integrated cost approaches. Seattle: Bill & 
Melinda Gates Foundation; 2008.
 46. Norman W, MacDonald C. Getting to the bottom of “triple bottom 
line.” Bus Ethics Q. 2004;14:243–62.
 47. Emerson J. The blended value proposition: integrating social and 
financial returns. Calif Manag Rev. 2003;45(4):35–51.
 48. Bragg R, Leck C. Good practice in social prescribing for mental 
health: The role of nature-based interventions. York, England: 
Natural England Commissioned Reports, Number 228. 2017.
 R. T. Edwards, C. L. Lawrence 
 49. Jones C, Hartfiel N, Brocklehurst P, Lynch M, Edwards RT. Social 
Return on Investment analysis of the Health Precinct commu-
nity hub for chronic conditions. Int J Environ Res Public Health. 
2020;17(14):5249.
 50. Arnold JL. The evolution of the 1936 flood control act. Fort Bel-
voir, Virginia: Office of History, US Army Corps of Engineers; 
1988.
 51. Hicks J. Classics and moderns: collected essays on economic 
theory, vol. 3. Cambridge: Harvard University Press; 1983.
 52. Adler MD, Posner EA. Rethinking cost-benefit analysis. Yale Law 
J. 1999;109(2):165–247.
 53. Atkinson G, Mourato S. Environmental cost-benefit analysis. 
Annu Rev Environ Resour. 2008;33:317–44.
 54. de Kinderen RJA, Wijnen BFM, Evers SMAA, Hiligsmann M, 
Paulus ATG, de Wit GA, van Gils PF, Over EA, Suijkerbuijk 
AW, Smit F. Social cost-benefit analysis of tobacco control 
policies in the Netherlands: Paul Van Gils. Eur J Public Health. 
2019;29(Suppl. 4):ckz185–793.
 55. de Wit GA, van Gils PF, Over EAB, Suijkerbuijk AWM, Lok-
kerbol J, Smit F, Spit W, Evers SM, de Kinderen RJ. Social cost-
benefit analysis of regulatory policies to reduce alcohol use in The 
Netherlands. Eur J Public Health. 2019;29(Suppl. 4):ckz185–794.
 56. van Meerkerk J, Verrips A, Hilbers H. A social cost benefit analy-
sis of road pricing in the Netherlands. The Hague, Netherlands: 
CPB Netherlands Bureau for Economic Policy Analysis. 2015. 
https:// www. cpb. nl/ sites/ defau lt/ files/ publi caties/ downl oad/ cpb- 
backg round- docum ent- social- cost- benefi t- analy sis- road- prici ng- 
nethe rlands. pdf. Accessed 10 May 2020.
 57. Weimer D. Behavioural economics for cost benefit analysis. Cam-
bridge: Cambridge University Press; 2017.
 58. Matjasko JL, Cawley JH, Baker-Goering MM, Yokum DV. 
Applying behavioral economics to public health policy: illus-
trative examples and promising directions. Am J Prev Med. 
2016;50(5):S13–9.
 59. Thaler RH, Sunstein CR. Nudge: Improving decisions about 
health, wealth, and happiness. London: Yale University Press; 
2008.
 60. Martin A, Pearson M. Kirklees District Sure Start Thornhill Eval-
uation Report. 2004. http:// www. ness. bbk. ac. uk/ suppo rt/ Annua 
lRepo rts/ docum ents/ 906. pdf. Accessed 20 June 2020.
 61. Kahneman D, Tversky A. Prospect theory: an analysis of decision 
under risk. Econometrica. 1979;47:263–91.
 62. Tversky A, Kahneman D. Rational choice and the framing of deci-
sions. J Bus. 1986;59(4 pt.2):S251–78.
 63. O’Reilly D, Hopkin J, Loomes G, Jones-Lee M, Philips P, McMa-
hon K, Ives D, Soby B, Ball D, Kemp R. The value of road safety: 
UK research on the valuation of preventing non-fatal injuries. J 
Transp Econ Policy. 1994;28(1):45–59.
 64. Ariss S, Foster A, Haywood A, Akparibo R, Mukuria C, Thomp-
son J, Holding E, Cooper R. Evaluation of the British Red Cross 
community connectors programme: final report, social return on 
investment. Sheffield, England: University of Sheffield; 2019.
 65. Tulla AF, Vera A, Guirado C, Valldeperas N. The return on invest-
ment in social farming: a strategy for sustainable rural develop-
ment in rural Catalonia. Sustainability. 2020;12(11):4632.
 66. Winrow E, Edwards RT. Effectiveness and stakeholder impact of 
the Sistema Cymru-Codi’r To music programme in north Wales: a 
social return on investment evaluation. Lancet. 2018;392(2):S93.
 67. Gafni A. Willingness-to-pay as a measure of benefits: relevant 
questions in the context of public decision making about health 
care programs. Med Care. 1991;29(12):1246–51.
 68. Ryan M, Gerard K, Amaya-Amaya M, editors. Using discrete 
choice experiments to value health and health care, vol. 11. 
Dordrecht: Springer Science & Business Media; 2007.
 69. Tockhorn-Heidenreich A, Ryan M, Hernández R. Discrete Choice 
Experiments. In: Facey K, Ploug Hansen H, Single A, editors. 
Patient involvement in health technology assessment. Singapore: 
Springer Nature; 2017. p. 121–33.
 70. Frör O. Bounded rationality in contingent valuation: empirical 
evidence using cognitive psychology. Ecol Econ. 2008;68:570–81.
 71. Trotter L, Vine J, Leach M, Fujiwara D. Measuring the social 
impact of community investment: a guide to using the wellbeing 
valuation approach. London: HACT. 2014. https:// www. hact. org. 
uk/ measu ring- social- impact- commu nity- inves tment- guide- using- 
wellb eing- valua tion- appro ach. Accessed 20 June 2020.
 72. Greenhalgh T, Schmid MB, Czypionka T, Bassler D, Gruer 
L. Face masks for the public during the covid-19 crisis. BMJ. 
2020;369:m1435.
 73. Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the 
precautionary principle: prioritizing treatment during a global 
pandemic. Nat Rev Clin Oncol. 2020;17:268–70.
 74. Begg I. The economic consequences of Covid-19. 2020. https:// 
blogs. lse. ac. uk/ europ pblog/ 2020/ 04/ 06/ the- econo mic- conse quenc 
es- of- covid- 19/. Accessed 18 June 2020.
 75. Rio Declaration on Environment and Development. Report of 
the United Nations Conference on environment and develop-
ment. 1992. https:// www. un. org/ en/ devel opment/ desa/ popul ation/ 
migra tion/ gener alass embly/ docs/ globa lcomp act/A_ CONF. 151_ 
26_ Vol.I_ Decla ration. pdf. Accessed 18 June 2020.
 76. Hill S. An investigation of economic evaluation methods for 
public health interventions: meeting the needs of public health 
decision-makers. Doctoral thesis, Newcastle University, Newcas-
tle, UK; 2019.
 77. Broome J. Trying to value a life. J Public Econ. 1978;9(1):91–100.
 78. Mishan EJ. The value of trying to value life. J Public Econ. 
1981;15(1):133–7.
 79. Culyer AJ, Cooper MH, editors. Health economics. London: Pen-
guin; 1973.
 80. British Household Panel Survey. https:// www. iser. essex. ac. uk/ 
bhps Accessed 29th Mar 2021.
 81. Understanding Society. https:// www. under stand ingso ciety. ac. uk/ 
about Accessed 29 Mar 2021.
 82. Crime Survey for England and Wales. 2015. http:// www. crime 
survey. co. uk/. Accessed 29 Mar 2021.
 83. Taking Part Survey. 2020. https:// www. gov. uk/ gover nment/ colle 
ctions/ taking- part. Accessed 29 Mar 2021.
 84. HM Government. Public services (Social Value) act 2012. https:// 
www. legis lation. gov. uk/ ukpga/ 2012/3/ enact ed. Accessed 29 Mar 
2021.
